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ttp://dx.doi.org/10.1016/j.jmoldx.2013.05.005We report the clinical and analytical performance of an isothermal thermophilic helicase-dependent
ampliﬁcation assay for blood Plasmodium parasite detection and species-level identiﬁcation. The
assay ampliﬁes the 18S rRNA gene fragment of all Plasmodium species and uses a species-speciﬁc
probe and a pan-malarial probe to deﬁnitively identify Plasmodium falciparum from other infec-
tious Plasmodium species. Amplicon-probe hybridization products are detected with a disposable
dipstick enclosed in a cassette. With a pan-malarialepositive and P. falciparumenegative result, an
additional test is performed to detect if the pan-malarialepositive band was the result of the
presence of Plasmodium vivax. The assay uses only 2 mL of human whole blood directly for a 50-mL
ampliﬁcation reaction, without any pre-ampliﬁcation processing. The clinical performance of the
assay was validated using 88 samples from New York patients suspected of malaria or babesiosis. The
overall sensitivity of the assay was 96.6% (95% CI, 87.3% to 99.4%), and the speciﬁcity was 100%
(95% CI, 85.4% to 100%), compared with gold standard microscopy and a laboratory-developed
molecular assay, respectively. The analytical sensitivity was 50 copies of DNA per assay or 200
parasites per microliter of blood, and the assay can detect samples with parasitemia levels <1%. This
novel molecular diagnostic assay requires minimal laboratory instrumentation and uses un-processed
blood as input; it can be readily performed in the ﬁeld. (J Mol Diagn 2013, 15: 634e641; http://
dx.doi.org/10.1016/j.jmoldx.2013.05.005)Supported by National Institute of Allergy and Infectious Diseases award
R43AI088787.
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tion, which supplied the tHDA ampliﬁcation reagents.Malaria is amosquito-bornedisease caused by intraerythrocytic
protozoa of the genus Plasmodium. Five Plasmodium species
are known to infect human beings: Plasmodium falciparum,
P. vivax, P. ovale, P. malariae, and P. knowlesi.1 People
infected by the malaria parasite experience fever, chills, and
a ﬂu-like illness that, if left untreated, may develop into severe
complications, potentially leading to death. The World Health
Organization reports that, in 2010, approximately 216 million
people were infected with malaria, and 655,000 died as a result
of their infection (WorldMalariaReport 2011,http://www.who.
int/malaria/world_malaria_report_2011/en, last accessed
June 24, 2013). Most fatalities (91%) occur in Africa, and are
due to infection by P. falciparum. Although relatively lessstigative Pathology
.severe than P. falciparum, P. vivax and P. ovale can enter a
dormant stage as hypnozoites in the liver of the host and cause
relapses by invading the bloodstream weeks, or even years,
later (Centers for Disease Control and Prevention, http://www.
cdc.gov/malaria/about/facts.html, last accessed June 24,
2013). Because P. vivax and P. ovale present a health risk
for travelers to the Middle East, Asia, South America, and
Central America, P. falciparum and P. vivax have different
Malaria Detection and Typing from Blooddrug-resistance proﬁles2; thus, species-speciﬁc identiﬁcation
is prudent if patients come from regions of the globe where
more than one species is present.
Although microscopy of stained thick or thin blood ﬁlm
smears remains the gold standard for diagnosis of malaria
infection, properly identifying the species of Plasmodium in
a patient’s blood is difﬁcult for western clinical laboratories.3
The rapid lateral-ﬂow antigen detection tests target the
histidine-rich protein ofP. falciparum and a pan-malarial lactose
dehydrogenase protein; however, the persistence of histidine-
rich protein of P. falciparum in patients receiving therapy
renders these rapid lateral-ﬂowantigen detection tests unsuitable
for monitoring clearance of the pathogen.4 Moreover, recent
reports on the deletion of theHRP2 gene from the Plasmodium
population in certain endemic areas have demonstrated that this
deletion results in signiﬁcantly higher false-negative diag-
noses.5,6 Rapid lateral-ﬂow antigen detection tests have good
sensitivity for P. falciparum but lack sensitivity for the other
species using the pan-malarial test line.7e9 Therefore, western
laboratories often perform a laboratory-developed nucleic acid
ampliﬁcation test to detect and further identify the species of
Plasmodium present in a patient’s blood.10,11
Several isothermal nucleic acid ampliﬁcation tests have
been developed to detect Plasmodium using loop-mediated
isothermal ampliﬁcation technology (LAMP).12e18 Some
of these tests do not offer species discrimination,16 whereas
others do distinguish between the species.15,18 Some target
the multicopy rRNA genes,12,17 whereas others target other
sequences also present in multiple copies in each cell.13,16
LAMP is viewed as a good platform for the detection of
malaria in the ﬁeld because it can be performed using
a constant temperature incubator or water bath,19 and it
allows for the detection of ampliﬁcation products using the
naked eye.20 However, the complexity of the LAMP reac-
tion, and its reliance on the use of six primer pairs, makes
LAMP assays more difﬁcult to manufacture than PCR tests,
and complicates assay design.21 In addition, the LAMP-
based assays still require dilution and heating of the blood
sample before isothermal ampliﬁcation,16 which potentially
increases the complexity of assay workﬂow.
In this study, we report the development of an alternative
isothermal nucleic acid ampliﬁcation platform that can detect
all ﬁve species of Plasmodium, and can speciﬁcally differ-
entiate P. falciparum and P. vivax parasites using a simple,
handheld, disposable detection device. The assay uses ther-
mophilic helicaseedependent ampliﬁcation (tHDA)22,23
chemistry to amplify the 18S rRNA genes24 of all Plasmo-
dium species, followed by a species-speciﬁc, probe-based
detection of P. falciparum versus the other Plasmodium
species. A reﬂex test, using one species-speciﬁc primer, is
performed to resolve P. vivax from P. ovale, P. malariae, and
P. knowlesi. Because tHDA can be performed using a small
amount (2 mL) of unprocessed blood and a dry heat block, this
assay has the potential of being used as a point-of-care device.
The sensitivity and speciﬁcity of this assay were evaluated
with a panel of 88 blood samples collected from eitherThe Journal of Molecular Diagnostics - jmd.amjpathol.orgsymptomatic travelers returning from malaria-endemic coun-
tries to the New York City area or patients from eastern Long
Island with a diagnosis of possible Babesia infection.
Materials and Methods
Control DNA
Genomic DNA of P. falciparum (3D7 strain) was puriﬁed
from laboratory cultureederived parasites by the Chelex
method.25,26 Brieﬂy, cultured 3D7 parasites were mixed with
red blood cells and normal human serum to achieve a ﬁnal
concentration of 50% hematocrit and 50% normal human
serum; then, they were spotted on Whatman ﬁlter paper and
allowed to dry at room temperature overnight. The dried ﬁlter
paper was soaked in sterile 0.5% saponin in PBS for 30
minutes at 37C. The ﬁlter paper was washed with sterile
PBS and treated with 200 mL of 5% Chelex 100 (Bio-Rad,
Hercules, CA) (preheated at 65C for 10 minutes) at 100C.
The supernatant obtained after centrifugation (2 minutes at
10,000  g) was respun to ensure complete removal of
Chelex. The resulting supernatant was stored at 20C until
further use. Dried blood spots of P. vivax, P. ovale, and P.
malariae on ﬁlter papers were obtained from the Malaria
Research and Reference Reagent Resource Center (Mana-
ssas, VA). DNA was extracted by the Chelex method, as
previously described. The total DNA concentration was
assessed by OD260 measurement. The OD260/OD280 ratio
was also measured, and the values were approximately 2.0,
indicating acceptable purity of the extracted DNA.
Plasmids carrying partial sequences of the 18S rRNA of
P. malariae, P. knowlesi, P. ovale, P. vivax, or the internal
control (IC) sequences were synthesized by BlueHeron
(Bothell, WA) by cloning the desired fragment of 200 to
400 bp into pUC vector.
Clinical Samples
Fresh negative human whole blood used in spiking experi-
ments was purchased from Research Blood Components
(Boston, MA). EDTA whole blood samples (n Z 88)
collected from 55 patients betweenOctober 2009 and January
2012 for routine diagnostic purposes, from either symptom-
atic travelers returning frommalaria-endemic countries to the
NewYork City area or patients from eastern Long Island with
a diagnosis of possible Babesia infection, were used for this
clinical evaluation. At sample collection, EDTA whole blood
samples were tested by thin-and-thick blood ﬁlm microscopy
and a nucleic acid sequenceebased ampliﬁcation malaria test
(NASBAMT) developed by a laboratory10,11 (North Shoree
LIJ Health System Laboratories, Lake Success, NY). Thirty-
nine samples from 20 patients contained P. falciparum,
16 samples from nine patients contained P. vivax, three
samples from two patients contained P. malariae, one sample
from one patient contained P. ovale, 15 samples from 10
patients contained Babesia species, and 14 samples from
13 patients were negative for both Plasmodium and Babesia.635
Figure 1 Alignment of P. falciparum, P. knowlesi, P. malariae, P. ovale, and P. vivax 18S rRNA sequences. The sequences were obtained from GenBank
(http://www.ncbi.nlm.nih.gov/nucleotide; accession numbers AL010278, L07560, AB489196, AJ001527, and U93233) for each species, respectively. Only the
region surrounding the tHDA ampliﬁcation product is shown. The primers and probes used in the two tHDA tests are indicated on the alignment.
Li et alSamples from the same patients were collected on different
days or at different times on the same day. Samples were
stored frozen at 80C until shipment to BioHelix Corpora-
tion (Beverly, MA) for the tDHA-based molecular tests.
Whole blood samples were de-identiﬁed in accordance with
a protocol approved by the Feinstein Institute for Medical
Research Institutional Review Board (Manhasset, NY). All
samples provided to BioHelix Corporation were stripped of
all patient identiﬁers and provided with a reference number.
Samples used for initial assay veriﬁcation contained Plas-
modium or Babesia or were negative for both. The initial
panel of samples (nZ 20) was provided with microscopy and
NASBAMT results. A second panel of samples (n Z 68)
containing various types of Plasmodium and Babesia and
samples negative for both blood parasites were provided
blinded (without microscopy and NASBAMT results) to
BioHelix Corporation.Table 1 Primer, Probe, and IC Sequences
Test no. Primer/probe Sequence
1 Forward primer 50-CTAGGCTGCACGCGTGCT
Reverse primer 50-TAATTGCAATAATCTATC
Probe for all 5 Plasmodium
species
50-GAAAAGTGTAGGTAATCT
Probe for P. falciparum 50-ATATTTGTATCTTTGCTT
Probe for IC 50-CCGCTATTTCATAGTAAG
IC 1 50-CTAGGCTGCACGCGTGCT
AAACCGCTATTTCATAGTA
GCCAAATCATCTAGCAAAC
ATCGTGATGGGGATAGATT
2 Forward primer 50-CGATTCAGCTTGCTGTTT
Reverse primer Same as in test 1
Probe for P. vivax Same as in test 1
Probe for IC Same as in test 1
IC 2 50-CGATTCAGCTTGCTGTTT
CTAAAACCGCTATTTCATA
TGTGCCAAATCATCTAGCA
CAAATCGTGATGGGGATAG
Forward and reverse primer-binding regions are underlined.
636Design of Primers, Probes, and ICs for tHDA
Ampliﬁcation
The tHDA-based malaria detection and typing assay con-
sisted of two separate tests. The ﬁrst test (test 1) detects all
ﬁve Plasmodium species, P. falciparum, P. vivax, P. ovale,
P. malariae, and P. knowlesi, known to infect humans. In
addition, it selectively identiﬁes the presence of P. falci-
parum. Primers for tHDA ampliﬁcation in test 1 were
designed using Primer3 software version 0.4.0,27 following
the speciﬁcations described in the IsoAmp III tHDA
ampliﬁcation kit (BioHelix Corporation). Primer pairs were
evaluated by real-time tHDA ampliﬁcation in the presence
of EvaGreen ﬂuorescent dye (Biotium, Hayward, CA). The
tHDA reaction conditions were then optimized using the
best-performing primer pairs. Asymmetric tHDA ampliﬁ-
cation conditions were evaluated with one of the primersLabel
Concentration
(nmol/L)
ACACTGATA-30 None 40
CCCATCACG-30 50 Biotin 120
TTATCA-30 30 DIG 50
ATATT-30 30 FAM 30
TC-30 30 DNP 30
ACACTGATACAACATTGACAACTA
AGTCCTTCGTCTATGACTATCTGT
TGCTAATCCAATTTATTTCATCAA
ATTGCAATTA-30
None 500 Copies
CGTA-30 None 50
None 100
30 DIG 30
30 DNP 30
CGTATTTTTCCTCAACATTGACAA
GTAAGTCCTTCGTCTATGACTATC
AACTGCTAATCCAATTTATTTCAT
ATTATTGCAATTA-30
None 2000 Copies
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Figure 2 Schematic diagram of the tHDA-based malaria assay results.
There are three antibody lines on the lateral-ﬂow test strip: anti-DNP, anti-
DIG, and anti-FAM (from top to bottom). In test 1, if only the DNP line
is present, the test result is negative for Plasmodium. If the FAM line is
present (the other two lines can be present or absent), the test result is
positive for P. falciparum. If the FAM line is absent, but the DIG line
is present (the DNP line can be either present or absent), the result is
positive for Plasmodium but negative for P. falciparum. In test 2, if only the
DNP line is present, the test result is negative for P. vivax; and if the DIG
line is present (the DNP line can be either present or absent), the test is
positive for P. vivax. The FAM line should always be absent for test 2.
Figure 3 Ampliﬁcation and detection of all ﬁve Plasmodium species and
identiﬁcation of P. falciparum and P. vivax by tHDA and lateral-ﬂow
cassettes. A: Test 1. Genomic DNA of P. falciparum (lane F) or plasmids
containing the 18S rRNA fragment of the other Plasmodium species (lanes V,
O, M, and K) were added to 50 mL of tHDA test 1 ampliﬁcation reaction to
a ﬁnal amount of 50 or 500 copies. B: Test 2. Plasmid DNA containing the 18S
rRNA fragment of P. vivax was added to tHDA test 2 at 50 copies per reaction
(lane V). Plasmid containing P. ovale, P. malariae, or P. knowlesi DNA frag-
ment or genomic DNA of P. falciparum was added to tHDA test 2 at 1000
limit of detection (ﬁnal 50,000 copies) per reaction (lanes F, O, M, and K). In
both A and B, the reactions were incubated at 64C for 90 minutes before the
tubes were applied to BESt cassettes. Negative reactions without input
template (NTC) were also performed (lane N). Each reaction was performed in
triplicate. In A, only NTC and reactions containing 50 copies of the input DNA
template were shown. Only one of the triplicates was shown for each reac-
tion. Label C on cassettes indicates the DNP line for IC; M, DIG line for
Plasmodium; and S, FAM line for P. falciparum.
Malaria Detection and Typing from Bloodlabeled with biotin at 50 and in excess to the other unlabeled
primer.
A digoxigenin (DIG)elabeled probe was designed to
anneal to a conserved region in the tHDA ampliﬁcation
product among all ﬁve Plasmodium species. A second probe
labeled with FAMwas designed to anneal speciﬁcally only to
P. falciparum but not the other four species. After ampliﬁ-
cation, the reactions were applied to BESt cassettes (Bio-
Helix Corporation). The probes annealed to the DNA strand
were generated by the biotin-labeled primer at room
temperature and were captured by anti-DIG or anti-FAM
antibody lines on a lateral-ﬂow test strip in the BESt
cassettes. Detection of the probe-amplicon complex was
achieved using streptavidin-coated color latex particles.28
An IC sequence was designed to be ampliﬁed by the same
primer pairs as the target amplicon, with a random sequence
in the middle between the primers. The IC sequence was
cloned into a pUC plasmid and included in the tHDA am-
pliﬁcation reaction. A probe labeled with 2,4-dinitrophenyl
(DNP) was designed to anneal to the IC sequence. The
ampliﬁcation products were detected on the lateral-ﬂow strip
by an anti-DNP antibody.
The second test (test 2), which serves as a reﬂex test,
detects the presence of P. vivax. Ampliﬁcation of P. vivax in
test 2 used the same reverse primer as in test 1. The forward
primer was designed to be speciﬁc for P. vivax and would not
amplify other Plasmodium species. The same DIG-labeled
detection probe in test 1 was also used in test 2. After
tHDA ampliﬁcation, the product was detected on the lateral-
ﬂow strip through anti-DIG antibodies. An IC sequence for
this test was designed similar to test 1. The IC sequence for
test 2 was the same as that for test 1, except for the forward
primer-binding region, which only binds the forward primer
for P. vivax. This IC sequence was also cloned into a pUC
plasmid and included in the reaction, and its ampliﬁcationThe Journal of Molecular Diagnostics - jmd.amjpathol.orgproduct was detected on the lateral-ﬂow strip through binding
to the same DNP-labeled probe as in test 1.
The DNP-labeled probe for the ICs was synthesized and
high-performance liquid chromatography puriﬁed by Tri-
Link (San Diego, CA). All other primers and probes were
synthesized and high-performance liquid chromatography
puriﬁed by Euroﬁns MWG Operon (Huntsville, AL).Assay Procedure
Both tHDA tests 1 and 2 were performed in a 50-mL reaction
volume. Test 1 contained 1 annealing buffer II (BioHelix
Corporation), 4 mmol/L MgSO4, 40 mmol/L NaCl, 3.6 mL
IsoAmp II dNTP mix (BioHelix Corporation), 40 nmol/L
forward primer, 120 nmol/L reverse primer, 50 nmol/L
DIG-labeled probe for all Plasmodium species, 30 nmol/L
FAM-labeledP. falciparumespeciﬁc probe, 30 nmol/LDNP-
labeled IC probe, 5 U of DdeI (New England Biolabs, Ips-
witch, MA), 150 ng extreme thermostable single-stranded
DNA binding protein (BioHelix Corporation), 500 copies of
the IC 1 IC plasmid, 2 mL IsoAmp III EnzymeMix (BioHelix
Corporation), and input template, as indicated in the ﬁgures
and text. Test 2 was performed in similar conditions as test 1,
except for the primers/probes and IC, which contained
50 nmol/L of theP. vivaxespeciﬁc forward primer, 100 nmol/
L reverse primer, 30 nmol/L DIG-labeled probe, 30 nmol/L
DNP-labeled IC probe, and 2000 copies of IC 2 IC plasmid.
The reaction mixture was allowed to incubate at 64C for 90637
Table 2 Parasitemia Level of the Malaria-Positive Clinical
Samples
Sample
No. of
samples
Range of
parasitemia
(%)
Mean
parasitemia
(%)
Median
parasitemia
(%)
P. falciparum 39 0.01e36.9 4.17 0.7
Others 20 0.03e2 0.55 0.39
All positives 59 0.01e36.9 2.98 0.5
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Figure 4 Histogram of the parasitemia levels of the positive clinical
samples. A: P. falciparumepositive samples. B: All other Plasmodium-
positive samples.
Li et al(without blood) or 120 (with blood) minutes. The reaction
tubes were applied to BESt cassettes after incubation, and
images were obtained 15 minutes later.
Determination of Analytical Sensitivity and Speciﬁcity
of the tHDA Assay
Genomic DNA from P. falciparum was extracted from
laboratory cultureederived parasites. The concentration of
the DNA was determined by OD260 measurement. Tenfold
serial dilutions (from 104 to 10 copies per mL) of the
P. falciparum genomic DNAwere used to determine the limit
of detection for the tHDA-based malaria test 1. Because
parasite cultures of the other four Plasmodium species could
not be obtained, plasmids containing a fragment of the 18S
rRNA region for P. vivax, P. ovale, P. malariae, and
P. knowlesiwere constructed, serially diluted (from 104 to 10
copies per mL), and used as templates to determine the
analytical sensitivity of test 1 for each of these four species
and that of test 2 for P. vivax. Each dilution was tested in
triplicate. High copy numbers (50,000) of either genomic
DNA from P. falciparum or plasmid DNA containing
a partial sequence of P. ovale, P. malariae, and P. knowlesi
were used to assess the speciﬁcities of test 2.
Ampliﬁcation by tHDA in the Presence of Unprocessed
Human Whole Blood
To test the effects of human blood on tHDA ampliﬁcation, 2
to 5 mL of fresh human whole blood (clinical test input
volume) was added to each 50-mL tHDA reaction test 1
containing 50 or 500 copies of P. falciparum genomic
DNA. Ampliﬁcation in the presence of human blood was
detected using BESt cassettes (BioHelix Corporation).
Determination of Clinical Sample Sensitivity and
Speciﬁcity
The 88 frozen EDTA whole blood samples were thawed at
room temperature just before the tHDA tests. To each of the
50-mL tHDA reactions in test 1, 2 mL of the blood sample
was added directly without heat denaturation or nucleic acid
extraction. Samples being identiﬁed by the tHDA test as
positive for Plasmodium (DIG-line positive) but negative
for P. falciparum (FAM-line negative) were subjected to test
2 to identify the presence or absence of P. vivax. The samples638were tested in tHDA assays either not blinded (n Z 20) or
blinded (n Z 68). Results were compared with microscopy
andNASBAMT. The analytical sensitivity of the tHDA assay
from human whole blood samples was evaluated by serial
dilutions of the frozen blood samples with known parasitemia
levels into fresh blood. Four P. falciparum samples with
parasitemia levels ranging from 0.3% to 8.8%were diluted up
to 2000-fold. The ﬁnal concentrations of the diluted samples
were between 100 and 250 parasites per mL of blood. Each
dilution was tested by tHDA test 1 in duplicates.
Results
Assay Overview
The tHDA-based malaria detection and typing assay con-
sisted of two separate tests. The ﬁrst test (test 1) detects all
ﬁve Plasmodium species, P. falciparum, P. vivax, P. ovale,
P. malariae, and P. knowlesi, known to infect humans.
In addition, it selectively identiﬁes the presence of
P. falciparum. The second test (test 2), which serves as
a reﬂex test, detects the presence ofP. vivax. Both tests 1 and 2jmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 3 Clinical Performance of the tHDA Assay Compared with
Microscopy/NASBAMT
Microscopy/NASBAMA
Positive Negative Total
P. falciparum
HDA Positive 38 0 38
Negative 1 49 50
Total 39 49 88
95% CI
Sensitivity (%) 97.4 84.9e99.9
Specificity (%) 100.0 90.9e100.0
P. vivax
HDA Positive 16 0 16
Negative 0 72 72
Total 16 71 88
95% CI
Sensitivity (%) 100.0 75.9e100.0
Specificity (%) 100.0 93.7e100.0
Other Plasmodium
HDA Positive 3 0 3
Negative 1 84 85
Total 4 84 88
95% CI
Sensitivity (%) 75.0 21.9e98.7
Specificity (%) 100.0 94.6e100.0
Overall
HDA Positive 57 0 57
Negative 2 29 31
Total 59 29 88
95% CI
Sensitivity (%) 96.6 87.3e99.4
Specificity (%) 100.0 85.4e100.0
Table 4 Analytical Sensitivity of the tHDA Malaria Assay
Sample
no.
Parasitemia
(%)
Fold of
dilution
Final
concentration
(parasites/mL)*
tHDA test
1 results
(positive/total)
NS-046 2.3 1000 115 1/2
NS-060 8.8 2000 220 1/2
NS-109 0.3 100 150 2/2
NS-110 1.1 333.3 165 1/2
*The parasite concentration in blood was calculated using the following
formulation: Number of Parasites/mL Z % Parasitemia  (5  106 Red
Blood Cells/mL)/(100  Fold of Dilution).
Malaria Detection and Typing from Bloodare based on isothermal ampliﬁcation of the 18S rRNA gene
(Figure 1) by tHDAplatform.22,23 In both tests, 2 mL of human
whole blood is added directly to the tHDA reaction mix for
DNA ampliﬁcation. No nucleic acid extraction or any other
type of sample preparation is necessary. The reactions are
incubated at a constant temperature of 64C for 2 hours.
During incubation, thermal stable UvrD helicase unwinds
double-stranded DNA template for hybridization to sequence
speciﬁc primers, which are subsequently extended by thermal
stable DNA polymerase.22,23 During ampliﬁcation, probes
labeled with either FAM or DIG hybridize speciﬁcally to the
target amplicon (Table 1 andFigure 1). The endproduct is then
detected using a disposable lateral-ﬂow strip by binding to
anti-FAM or anti-DIG antibodies.28 In both tests, an IC
plasmid was included in the reaction mix to monitor the
ampliﬁcation and was detected through a DNP-labeled probe
on the lateral-ﬂow strip (Table 1 and Figure 2).
Analytical Sensitivity and Speciﬁcity
For all ﬁve species, the tHDA-based malaria assay test 1 was
able to detect as low as 50 copies of input template DNAThe Journal of Molecular Diagnostics - jmd.amjpathol.org(genomicDNAforP. falciparum and constructedplasmidDNA
containing sequences of the other four species) per reaction
(Figure 3A).This test also successfully identiﬁed the presence of
as low as 50 copies of P. falciparum per reaction (Figure 3A).
The speciﬁcity of the P. falciparum probe was demonstrated by
the absence of the FAM line in the tests using any of the other
four Plasmodium species as input template (Figure 3A).
Similarly, test 2 detected 50 copies of the plasmid con-
taining the P. vivax 18S rRNA fragment at 50 copies per
reaction (Figure 3B). The ampliﬁcation was speciﬁc for P.
vivax. The test result was negative (Figure 3B) when 50,000
copies, which was 1000 the limit of detection of this test,
of P. falciparum, P. ovale, P. malariae, or P. knowlesi were
used as input template.
Although puriﬁed genomic DNA from Plasmodium
species other than P. falciparum could not be obtained, total
DNA from dried blood papers containing P. falciparum,
P. vivax, P. ovale, and P. malariae was used to further
verify the ability of test 1 to detect genomic DNA from
these species. Different amounts (from 1 to 0.05 mL) of each
extracted sample were added to the 50-mL test 1 reaction
mix. The test was able to detect all four species using as low
as 0.05 mL of sample input (data not shown).
Effect of Human Whole Blood on tHDA Ampliﬁcation
The effect of human whole blood on tHDA ampliﬁcation
was evaluated using test 1. Our results demonstrated that the
presence of 2 mL of human whole blood did not inhibit
tHDA ampliﬁcation. When 2 mL of whole blood was added
to the 50-mL reaction mix of test 1, the analytical sensitivity
of 50 copies per reaction was not compromised (data not
shown). When the volume of the blood increased to 5 mL
per reaction, we started to observe failure of ampliﬁcation
and detection when the target input was close to the limit of
detection of 50 copies (data not shown).
Clinical Sensitivity and Speciﬁcity
Among the 88 EDTA whole blood samples, 59 were iden-
tiﬁed as positive for malaria by microscopy/NASBAMT.
These 59 samples contained various types of Plasmodium,
with 39 P. falciparum, 16 P. vivax, 3 P. malariae, and 1 P.
ovale. The parasitemia levels range from 0.01% to 36.9%
(median, 0.5%), with most (n Z 37) of the 59 positive639
Li et alsamples being <1%. Ten of them were <0.1% (Table 2 and
Figure 4). The ﬁve lowest parasitemia levels were 0.01%,
0.03%, 0.03%, 0.05%, and 0.05%.
The tHDA malaria assay test 1 identiﬁed 57 of the 59
microscopy/NASBAMT-positive malaria samples as posi-
tive for Plasmodium, of which 38 were identiﬁed as P.
falciparum by tHDA. One sample, identiﬁed as P. falcipa-
rum by microscopy/NASBAMT with a parasitemia level of
0.05%, was negative by tHDA. Among the 20 noneP.
falciparum malaria samples, 19 were identiﬁed by tHDA as
Plasmodium positive but P. falciparum negative (16 P.
vivax, 2 P. malariae, and 1 P. ovale by microscopy/NAS-
BAMT). These samples were subjected to test 2, which
identiﬁed the 16 P. vivax samples as positive for P. vivax.
The two P. malariae samples and one P. ovale sample were
identiﬁed by tHDA test 2 as negative for P. vivax. One
sample was identiﬁed by tHDA as malaria negative but by
NASBAMT as P. malariae. This sample was also negative
by microscopy. The 14 negative and 15 Babesia samples
were all identiﬁed by tHDA assay as negative for Plasmo-
dium. Overall, compared with combined microscopy and
NASBAMT results, the tHDA malaria assay resulted in
a sensitivity of 96.6% (95% CI, 87.3% to 99.4%) and
speciﬁcity of 100% (95% CI, 85.4% to 100%) (Table 3).
The analytical sensitivity of the tHDA assay from human
whole blood samples was evaluated by serial dilutions of the
frozen blood samples with a known parasitemia level into
fresh blood. Four P. falciparum samples with parasitemia
levels ranging from 0.3% to 8.8% were diluted up to 2000-
fold. The ﬁnal concentrations of the diluted samples were
between 100 and 250 parasites per mL of blood. Each
dilution was tested by tHDA test 1 in duplicate. All four
samples were positive by tHDA test for at least one of the
duplicates (Table 4). These results suggested that the
sensitivity of the tHDA assay was approximately 200
parasites per mL of blood.
Discussion
The tHDA-based malaria assay demonstrated the capability
of detecting the ﬁve malaria causing Plasmodium species
using only 2 mL of unprocessed human whole blood without
the need for nucleic acid extraction. The tHDA ampliﬁca-
tions were performed under isothermal conditions at
a constant temperature of 64C, which can be performed in
a simple dry heat block or water bath. The detection of the
target-speciﬁc ampliﬁcation products was achieved by
single-use disposable lateral-ﬂowebased cassettes.
The tHDA-based malaria assay was able to identify the
two most common Plasmodium species, P. falciparum
and P. vivax. P. falciparum causes approximately 81% of
total malaria worldwide (World Malaria Report 2011), with
P. vivax making up the rest.29 P. falciparum is the most
dangerous cause of malaria, with the highest mortality rate
(World Malaria Report 2011). P. vivax is often nonfatal, but
more widespread, than P. falciparum (World Malaria Report6402011). It is believed to account for 70 to 80 million cases
annually (ie, 34% of the global incidence and 56% of malaria
cases outside of Africa).29 Moreover, P. vivax can cause
relapses years after the initial infection if not completely
eradicated (Centers for Disease Control and Prevention,
http://www.cdc.gov/malaria/about/facts.html). In contrast,
the incidence of the other species of Plasmodium is seldom
discussed in the literature. P. falciparum and P. vivax also
have different drug-resistance proﬁles.2 Therefore, the ability
of the tHDA assay for species-speciﬁc identiﬁcation would
help determine the proper treatment in a timely manner,
especially in regions where more than one species is present.
The analytical sensitivity of the tHDA-based assay was
50 copies of Plasmodium genomic DNA or plasmid, in the
presence of 2 mL of human whole blood spiked into the 50-
mL reaction. Compared with the analytical sensitivity using
pure DNA with spiked blood, the analytical sensitivity using
patient samples was approximately 5 to 10 times lower
(approximately 200 parasites per mL of blood). This could
be because of the fact that, after long-term storage and
repeated freeze and thaw, the parasite DNA might have
partially degraded or the quality of the blood may have
caused some inhibition to tHDA reactions. These possibil-
ities can be tested in future studies by using fresh blood
samples as a template for tHDA ampliﬁcation.
In summary, the combination of the two tHDA tests
offers a simple, cost-effective way to detect Plasmodium
species and identify P. falciparum and P. vivax in un-
pressed blood without a sample preparation step. The
work ﬂow renders the assay essentially instrument free,
eliminating the need for costly thermocyclers required for
molecular diagnostic assays based on PCR. The tests can
also be performed in a random access manner, allowing
for on-demand testing that would be particularly beneﬁ-
cial for the rapid diagnosis of malaria and other blood-
borne parasites, such as Babesia, in persons seen in
both emergency departments and urgent care centers.
Potentially, this assay can be developed as a low-cost and
fast turnaround point-of-care assay performed in the ﬁeld
by people with minimal training.Acknowledgment
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